11/28/2016 - 1:09pm

Both companies have confirmed that they are in preliminary discussions. 

11/22/2016 - 2:36pm

Xultophy was approved the same day as Sanofi’s Soliqua 100/33, and the two are among the first in a new class of drugs that combine a GLP-1 agonist and long-lasting insulin.

11/22/2016 - 1:29pm

Soliqua 100/33 combines Lantus and lixisenatide, a GLP-1 receptor agonist, in a once-daily injection.

11/21/2016 - 2:01pm

Diplomat has begun dispensing Shire’s recently launched primary immunodeficiency treatment. 

11/18/2016 - 1:11pm

According to the US Center for Disease Control and Prevention, immunizing pharmacists now administer roughly 25% of all influenza vaccinations.

11/17/2016 - 1:15pm

Intarosa is a treatment for postmenopausal women experiencing pain during sex, a condition known as dyspareunia and a symptom of vulvar and vaginal atrophy. The condition is the result of a decline in estrogen levels that occurs during menopause. 

11/17/2016 - 12:59pm

James Meyers joined Gilead as a regional sales director and has been the company’s SVP North American commercial operations since 2007.

11/16/2016 - 11:41am

The drug, which was approved in September, is indicated to treat adult and pediatric patients aged two years and over with primary immunodeficiency — a group of more than 300 genetic disorders that prevent the immune system from functioning properly. 

11/16/2016 - 9:43am

First order of business for Veru's new VP marketing will be to oversee the roll-out of FC2 as a prescription product, including establishing the infrastructure necessary for facilitating reimbursement under the Affordable Care Act.